Evusheld (COVID-19 coronavirus cure)

2023: US revokes license from "cocktail" against coronavirus

On January 26, 2023 USA , the company revoked its permission to use Evusheld. AstraZeneca This medicine, which was created for, treatment of infection COVID-19 was not effective in more than 90% of coronavirus subvariants.

The omicron XBB.1.5 subvariant, which can evade antibodies that block infection, has grown rapidly in the United States and is responsible for 49% of cases as of January 30, 2023, according to the US Centers for Disease Control and Prevention. Evusheld is also not effective against subvariants BQ.1, BQ.1.1, and XBB. Together with XBB.1.5, subspecies of COVID-19 that are resistant to Evusheld account for almost 93% of new cases in the United States.

People with weakened immune systems, such as those undergoing chemotherapy for cancer and patients who have had their organs transplanted, are among the groups most vulnerable to severe diseases caused by the drug Evusheld. Many take as an additional layer of protection because vaccines do not induce a strong immune response in them. Evusheld is taken as a preventive before contact with COVID-19. This is a combination of antibodies, cilgavimab and tixagevimab given as two injections every six months.

Evusheld (COVID-19 coronavirus cure)

FDA Just over 1 million doses of Evusheld have been distributed in the US since the December 2021 injection authorization, according to health care the US Department of Human Services. About 720 thousand of these doses were actually administered to patients.

Actions to limit the use of Evusheld for January 2023 prevent patients from being exposed to possible side effects from the drug, such as allergic reactions that could be potentially serious, at a time when less than 10% of the infection-causing variants circulating in the U.S. are susceptible to the drug, the FDA said in a statement.

As of January 2023, there is no replacement for Evusheld. Dr. Ashish Jha, head of the White House task force on COVID-19, accused Congress of reducing the number of cases of treatment. Jha reported that the inability of lawmakers to accept additional funding from COVID-19 means that the US government does not have investments to further develop vaccines for other strains against this pandemic. Jha urged the lives of the country to consult with their doctors about the right steps to protect, as well as take additional precautions.

As of January 30, 2023, more than 7 million adults in the United States have a weakened immune system for 10 different types of COVID-19 stamp. They account for about 12% of hospitalizations caused by the COVID-19 virus, although they make up only 3% of the population, according to a study by the US Center for Disease Control and Prevention.^[1]

Notes